Cargando…
Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts
Malignant mesothelioma (MM) is a rare disease often associated with environmental exposure to asbestos and other erionite fibers. MM has a long latency period prior to manifestation and a poor prognosis. The survival post-diagnosis is often less than a year. Although use of asbestos has been banned...
Autores principales: | Nabavi, Noushin, Wei, Jingchao, Lin, Dong, Collins, Colin C., Gout, Peter W., Wang, Yuzhuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040159/ https://www.ncbi.nlm.nih.gov/pubmed/30022998 http://dx.doi.org/10.3389/fgene.2018.00232 |
Ejemplares similares
-
Switching off malignant mesothelioma: exploiting the hypoxic microenvironment
por: Nabavi, Noushin, et al.
Publicado: (2016) -
Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant Mesothelioma
por: Shrestha, Raunak, et al.
Publicado: (2020) -
Next generation patient-derived prostate cancer xenograft models
por: Lin, Dong, et al.
Publicado: (2014) -
Aneustat (OMN54) has aerobic glycolysis‐inhibitory activity and also immunomodulatory activity as indicated by a first‐generation PDX prostate cancer model
por: Qu, Sifeng, et al.
Publicado: (2018) -
Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer
por: Qu, Sifeng, et al.
Publicado: (2018)